Medication-info.com Search Menu

Cathflo Activase (Alteplase): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Being discontinued since May 21, 2026
Strength:
50 mg/50 mL, 100 mg/100 mL
Active ingredient:

Patient information: uses, side effects, how to take - Cathflo Activase

INSTRUCTIONS FOR USE

Activase®

(alteplase) for injection

for intravenous use

100 mg (58 million IU)

Read before preparing Activase®

See also enclosed, full prescribing information

Instructions for Use should accompany reconstituted Activase to patient bedside.

Kit Contents
Transfer device

Activase vial

(no vacuum)

Activase vial stopper parts:

Sterile Water for Injection (water) vial

Note: Do not use Bacteriostatic Water for Injection, USP.

Prescribing Information

Instructions for Use

Also Required

(not included in kit)

1 Luer syringe for removing bolus dose, as needed

1 Luer syringe for removing excess volume, as needed

2 large bore needles

2 Alcohol swabs

IV infusion set

Reconstitution (use aseptic technique)
Step 1: CleaningStep 2: Spiking Water vialStep 3: Spiking Activase vial
  • Remove caps from both vials.
  • Wipe each stopper with a separate alcohol swab.
  • Remove cover from one end of transfer device. Do not wipe transfer device spikes with alcohol. (Note: Either side of transfer device can be used).
  • Insert spike straight through center of water vial stopper.

Do not invert water vial yet. Inverting too early may lead to leakage and incorrect dosing.

  • Remove cover from other end of transfer device.
  • Hold Activase vial upside down over spike.
  • Press Activase vial down to insert spike straight through center of Activase vial stopper.

Inserting the spike off-center could lead to stopper collapse.

Reconstitution (use aseptic technique)Administration Warning
Step 4: Inverting and transferringStep 5: Inspecting
  • Invert vials so that water vial is on top.
  • Allow all water to transfer into Activase vial.
  • If the flow does not start immediately or pauses, initiate the flow by flipping and re-inverting the vials.
  • Swirl gently and/or invert slowly to dissolve Activase powder.

Do not shake vials. Shaking may lead to excessive foaming and degraded medication.

  • Separate empty water vial and transfer device from Activase vial.
  • Reconstituted Activase vial (1 mg/mL) should be:

    • Colorless to pale yellow and transparent
    • Free of particulates
  • If needed, let stand undisturbed for a few minutes to allow large bubbles to dissipate.

Review important information below before continuing to Step 6.

Do not push air from the syringe into the vial.

The vial is not under vacuum and adding air at any time may result in leakage and incorrect dosing.

Only insert needles within center ring of stopper, away from hole made by transfer device.

Insert needle within center ring of stopper, away from the hole made by transfer device when withdrawing medication to avoid leakage and incorrect dosing. Do not insert needles outside of the center ring of stopper.

Administration (use aseptic technique)
Step 6: Preparing bolusStep 7: Removing excess volumeStep 8: Spiking and hanging
  • Check if bolus is needed. If yes, attach needle to empty Luer syringe.
  • Insert needle once through center ring of stopper, away from hole made by transfer device, and slowly withdraw the bolus amount.
  • Check if there is excess volume in vial. If yes, attach needle to empty Luer syringe.
  • Insert needle once through center ring of stopper, away from hole made by transfer device, and slowly withdraw the excess volume.
  • Insert spike from IV tubing set into center of vial stopper, through same hole made by transfer device.
Do not push any air from syringe into vial (may cause leakage). Do not push any air from syringe into vial (may cause leakage). Do not make a new hole in the vial stopper. Additional holes in vial stopper may lead to leakage.
  • Alternatively, the bolus can be left in the vial and administered via an infusion pump or removed from a port on the infusion line.
  • Discard any excess volume.
  • Leave infusion dose in vial.
  • Peel clear plastic hanger from vial label.
  • Hang on IV pole and administer per facility protocol.

Administration Notes

  • Activase is for intravenous administration only.
  • Do not add any other medication to infusion solutions containing Activase.
  • Extravasation of Activase infusion can cause ecchymosis or inflammation. If extravasation occurs, terminate the infusion at that IV site and apply local therapy.
  • See full prescribing information for alternative dilution instructions.

Storage & Stability

  • Store lyophilized Activase at controlled room temperature not to exceed 30°C (86°F), or under refrigeration at 2° to 8° C (36° to 46° F). Protect the lyophilized material during extended storage from excessive exposure to light.
  • Activase contains no antibacterial preservatives and must be used within 8 hours following reconstitution (when stored at 2-30°C).

Manufactured by:

Genentech, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

U.S. License No. 1048

Activase® (alteplase) is a registered trademark of Genentech, Inc.

©2025 Genentech, Inc. All rights reserved.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Revised: February/2025

Representative sample of labeling (see the HOW SUPPLIED section for complete listing):

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: BLA 103172 · View the label on DailyMed

Revision date stated in the text: February 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Cathflo Activase

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Active ingredient Alteplase
Dosage form Kit
Marketing status listed in the FDA NDC Directory
Company (applicant) GENENTECH
FDA approval BLA 103172Biologics License Application (BLA) Approved November 13, 1987
Manufacturers 1 labelers list this drug on DailyMed
Drug shortage
  • Being discontinued since May 21, 2026
Packages (NDC)
Package
50 mg/50 mL – 1 in 1 carton NDC 50242-044-13
100 mg/100 mL – 1 in 1 carton NDC 50242-085-27

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.